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ABSTRACT
Growing interest had been focused on the involvement of the small airways in asthma, and impulse oscillome-
try (IOS) has been utilized as pulmonary functions for detecting large and small airways diseases separately.
IOS can measure respiratory resistance and reactance at multiple frequencies, not available by spirometry or
body plethysmography, is non-invasive techniques and convenient for elderly patients with a low dependency
on cooperation during tidal breathing. IOS indices were well correlated with not only predicted FEV1 but also
FEF25-75, residual volumetotal lung capacity, delta N2 of a single nitrogen washout test which representing
air trapping and inhomogeneous ventilation in the distal lung. These parameters and QOL scores were im-
proved by additional transdermal long-acting beta-2 agonist patch even in well-controlled elderly asthma treat-
ing with inhaled corticosteoids alone. IOS may have a complementary role of spirometry in detecting subtle air-
ways changes in general practice. However, systemic studies are required to investigate the clinical implication
of each IOS index.
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ABBREVIATIONS
IOS, impulse oscillometry; COPD, chronic obstructive pulmonary disease; FOT, forced oscillation technique; R,
resistance; X, reactance; Fres, resonant frequency at reactance zero; FEF25-75, forced expiratory flow at 25%
to 75% of forced vital capacity; VC, vital capacity; FEV1, forced expiratory volume in one second; RV, residual
volume; TLC, total lung capacity; ICS, inhaled corticosteroid; SBNW, a single-breath nitrogen washout; ACT,
asthma control test; LABA, long-acting beta-2 agonist; QOL, quality of life.
INTRODUCTION
Impulse oscillometry (IOS) is a type of forced oscilla-
tion technique (FOT), which can evaluate respiratory
resistance (R) and reactance (X) at various oscillatory
frequencies, which cannot be measured by spirome-
try and body plethysmography. In recent years, IOS
is increasingly used in many clinical researches as
pulmonary function parameters in asthma and
chronic obstructive pulmonary disease (COPD).1-8
IOS is convenient for elderly patients and chiledren
with a low dependency on cooperation during tidal
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breathing. And changes in R measured by IOS during
methacholine challenge correlated better with
asthma symptoms than traditional spirometric meas-
ures, implying a higher sensitive index.3 IOS parame-
ters correlated better with clinical symptoms and
asthma control than spirometry indices.9 However,
clinical implication of each IOS index remains under
discussion.
Elderly asthma is critical and over 85% of asthma
death appears in over 65 year-old people in Japan.
Pathophysiological and clinical characteristics of eld-
erly asthma are 1) prominent small airways impair-
ment comparing with young adults, 2) non-allergic
type, 3) high rate co-morbidity of COPD, heart dis-
eases, gastroesophagial reflex, 4) poor inhalation
technique and poor adherence. Recent recommenda-
tion on the appropriate use of long-acting beta-2 ago-
nist (LABA) by U.S. FDA (June 2, 2010) said LABA
should be used only in asthmatic patients with inade-
quate control although inhaled corticosteroid (ICS)
use.
In this review, we describe follows 1) assessment
of small airways disease using traditional pulmonary
function tests, 2) advantage and demerit of IOS, 3)
correlation between IOS and traditional pulmonary
function tests, 4) add-on effects of transdermal LABA
patch on small airways impairment in elderly asthma
who receiving ICS assessed by IOS.
ASSESSMENT OF SMALL AIRWAYS FUNC-
TION IN TRADITIONAL PULMONARY FUNC-
TION TESTS
Increasing evidences demonstrate that small airways
function is associated with asthma control,9-13 and
small airways disease is critical therapeutic target.
Extensive pulmonary obstructive disease can be pre-
sent in the small airways with little abnormality in tra-
ditional pulmonary function tests, therefore the small
airways are sometimes referred to as the ‘silent zone’.
In general practice, conventional spirometry has a
limited capacity to distinguish the small and large air-
ways. Peak expiratory flow (PEF) and forced expira-
tory volume in one second (FEV1) mainly reflect the
large airways function, on the other hand FEF25-75 is
believed to represent small airways function,14 but it
suffers from poor reproducibility.15 Residual volume
(RV) divided by total lung capacity (TLC) measured
using body plethysomography is one of the index of
air-trapping due to small airways narrowing. Another
examination assessing heterogeneity of peripheral
lung ventilation is delta N2; gradient of the slope of
the nitrogen alveolar plateau at phase III in a single-
breath nitrogen washout (SBNW) test.15 In recent
years, non-invasive physiological parameters of alveo-
lar nitric oxide, multiple-breath nitrogen washout
test, and FOT including IOS can identify airways re-
sponse from large and small airways.17
IOS
IOS uses flow oscillations generated by a loud
speaker that are superimposed on tidal breathing.
The resulting pressure and low changes are assessed
by Fourier analysis to determine respiratory imped-
ance; resistance and reactance, at multiple frequen-
cies. A commercially available IOS machine (Master
Screen-IOS; CareFusion, Germany) fulfils the stan-
dard recommendation,18,19 therefore in this review
we describe about this machine. Rectangular me-
chanical impulses containing a continuous power
spectrum of 0-100 Hz are generated by a simple on
off control switch on a loudspeaker through a mouth-
piece during tidal breathing. The impulse is having
the interval of 0.2 second, and impulse duration is
about 45 milli second. The patients support their
cheeks and mouth floor to reduce upper airway
shunting while tests are performed. Impedance meas-
urements including R and X from 5 to 20 Hz (R5, R20,
and X5) and resonant frequency reactance (Fres),
which represents the Hz at which the negative reac-
tance reaches zero (Fig. 1). Integrated area of low-
frequency reactance (AX) is also calculated as shown
in Figure 1. We implicated R5 as a index of total air-
way resistance, R5-R20 (the fall in resistance from 5
to 20 Hz), X5, AX, and Fres as indices for small air-
way disease, and R20 for a value of large air-
ways.4,5,20-23 Reliability of IOS indices were evaluated
within- and between-day, and coefficient of variation
were under 10%.24,25
Dellaca et al.26-28 indicated that respiratory system
reactance measured by FOT changed to be more
negative value during flow-limited expiration in pa-
tients with COPD. When airflow limitation is present,
oscillometory signal cannot pass through the choke
points to reach the alveoli,29 resulting in a marked re-
duction apparent compliance and thus the value of X5
change to be more negative physiologically.30 The
with-in breath changes in X5 have been suggested to
reflect the number of choke points present and over-
all distribution within the bronchial tree, and to repre-
sent the overall distribution of expiratory flow limita-
tion during tital breathing.26-28 In COPD, as airflow
obstruction worsens, expiratory flow limitation ap-
pears as much lower flow for a given lung volume and
becomes present at rest or at least early during exer-
cise.31 There is evidence that IOS and plethysmogra-
phy are more sensitive than spirometry for detecting
bronchodilator effects in patients with asthma and
COPD.2,32 And airway resistance measured by IOS
during methacholine challenge correlated better with
asthma symptoms than traditional spirometric meas-
ures implying a higher sensitive index.3 Recently,
Takeda et al.9 reported that IOS parameters corre-
lated better with clinical symptoms and asthma con-
trol than spirometry indices in asthmatic patients.
IOS in Elderly Asthma
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Fig.　1　Schematic illustration of impulse oscillometry indices over oscillation frequency, 
including R5, R20, R5-R20, Fres, X5, and AX. Upper represents the pattern during exac-
erbation of asthma and lower demonstrates stable period.
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CORRELATIOS BETWEEN IOS AND TRADI-
TIONAL PULMONARY FUNCTION TESTS
We reported that relationship between IOS indices
and traditional pulmonary function tests were per-
formed in 80 stable elderly asthmatic patients (>65
years) treating with inhaled corticosteroids.33 This
study approved by the Ethic Committee at Sapporo
Medical University, and written informed consent
was obtained from all patients. Spirometry and body
phretisomography using CHESTAC-8800 (Chest, To-
kyo, Japan) were done after IOS examination. TLC
and RV were determined by the helium gas dilution.
The best of three consecutive examinations was re-
corded. Finally, SBNW test assessing heterogeneity
of small airway obstruction using CHESTAC-8800
filled with 100% oxygen and equipped with a nitrogen
meter connected to the mouthpiece, allowing con-
tinuous sampling.16 The expiratory nitrogen concen-
tration (%N2) was plotted against lung volume (be-
tween TLC and RV), producing the expiratory nitro-
gen washout curve. The slope of the nitrogen alveolar
plateau (delta N2, phase III) was calculated by draw-
ing the best-fit line through phase III of the expira-
tory volume-concentration curve.
Results are shown in Table 1. Total respiratory re-
sistance of R5 was best correlated with PEF. Fres and
R5-R20 evaluated by IOS were good correlated with
traditional lung function tests of small airways ob-
struction and heterogeneity lung ventilation of pre-
dicted FEV1, FEF25-75, RVTLC, and delta N2 in eld-
erly asthma. Therefore R5-R20 and Fres may be new
indices for small airways disease, with little intension
of patients.
Previously, Yamaguchi et al.5 reported that IOS pa-
rameter of R5-R20 had a good correlation with FEF
25-75 or RVTLC, therefore R5-R20 seems to be a
good maker for detection for small airways disease.
On the other hand Tsuburai et al.34 recently de-
scribed Fres was best correlated to predicted FEV1
and predicted FEF25-75 using a Mostgraph (Chest,
Tokyo, Japan) machine which is another type of FOT
available in Japan. These results suggested that IOS
indices of R5-R20 and Fres seems to be small airways
dysfunction presenting heterogeneity of small air-
ways narrowing consequently uneven ventilation of
the lung. In contrary, R5 may indicate total airway
narrowing.
Tanaka H et al.
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Table　1　Correlation between traditional pulmonary function tests and impulse oscillometry in elderly asthma (n = 80) using 
simple linear regression analysis
IOS indices PF(L/sec)
pFEV1
(%)
FEF25-75
(L/sec)
RV/TLC
(%)
Delta N2
(%)
Resistance R5 -0.61** -0.64** -0.56** 0.40** 0.27**
R20 -0.57** -0.50** -0.46** 0.24* ns
R5-R20 -0.46** -0.61** -0.49** 0.46* 0.32**
Reactance X5 0.45** 0.53** 0.41** -0.37** ns
Ax -0.44** -0.58** -0.44** 0.43** 0.24*
Resonant frequency Fres -0.56** -0.66** -0.60** 0.49** 0.43**
FEV1, forced expiratory volume in one second; FEF25-75, mid-forced expiratory fl ow; RV, residual volume; TLC, total lung capacity; VC,
vital capacity; Delta N2, slope of phase III at the single-breath N2 washout; R5, respiratory resistance at 5 Hz; R20, respiratory resistance at 
20 Hz; X5, reactance at 5 Hz; AX, integrated of negative value of reactance from 5 Hz t zero; Fres, frequency at which reactance is zero; 
ns, not siginifi cant.
**p < 0.05, *p < 0.01. 
Table　2　Baseline characteristics of the two groups in elderly asthma (n = 33)
LABA add on Control p
Patients (n) 16 17 -
Age (years) 70.2 ± 7.17 70.3 ± 6.45 0.9644*1
Sex (%)
Male 7 (43.8) 6 (35.3)
0.7283*2
Female 9 (56.3) 11 (64.7)
Severity by JPGL (%)
Mild 4 (25.0) 8 (47.1)
0.1948*3Moderate 12 (75.0) 9 (52.9)
Severe 0 0
ICS (%)
FP 6 (37.5) 7 (41.2)
0.8919*2
BDP 4 (25.0) 3 (17.6)
BUD 4 (25.0) 3 (17.6)
CIC 2 (12.5) 4 (23.5)
Tobacco (%)
Non-Smokers 10 (62.5) 13 (76.5)
0.4646*2
Ex-Smokers 6 (37.5) 4 (23.5)
ACT (score) 21.9 ± 1.69 22.5 ± 1.50 0.4162*3
*1 t-test, *2 Fisher’s Ecact test, *3 Wilcoxon rank sum test. 
JPGL, Asthma Prevention and Management Guideline 2009, Japan (in Japanese).
TRANSDERMAL LABA FOR ELDERLY AST-
HMATICS
Transdermal LABA patch of tulobuterol, sustains a
release of effective blood concentration for 24
hours,35,36 which has been developed in Japan. Its ad-
hesive layer is stable when attached to a mildly fat-
soluble, and serves as a drug container because its
reservoir system retains tulobuterol as crystal. This
unique transdermal LABA is applied to mild to severe
persistent asthmatic patients in Japanese Guideline
for the Diagnosis and Treatment of Allergic Diseases
2010 (in Japanese). This patch has two advantages; 1)
available for elderly people who has poor inhalation
technique, 2) available when strong cough persists
during asthma exacerbation, on the other hand, one
disadvantage is dermatitis but its frequency is a few.
We assessed the additional effects of this transder-
mal LABA on small airways disease using IOS in eld-
erly asthmatics. This study is muti-center, open-
labeled, age-matched, and 4-week treatment of 2 mg
of tulobuterol patch, approved by the Ethic Commit-
tee at our hospital and clinic, and written informed
consent was obtained from all patients. Patients with
chronic obstructive pulmonary disease and heat dis-
eases were excluded. A total of 33 stable elderly asth-
matics treating with inhaled corticosteroid (ICS)
monotherapy divided into two groups; treatment (n =
16, Group T) and control (n = 17, group C) (Table 2).
We measured IOS indices and asthma control test
(ACTTM)37 before and after the therapy. GlaxoSmith
Kline (Tokyo, Japan), the developer of the ACTTM,
IOS in Elderly Asthma
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Fig.　2　Therapeutic changes in IOS indices before and after 4-week treatment in LABA add on group and control group. a, 
R5; b, R20; c, R5-R20; and d, Fres. All paired within-subject data were evaluated using the Wilcoxon signed rank test, and 
paired within-group data were assessed by the Wilcoxon rank sum test.
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provides written permission for its use. In addition,
we evaluate within-breath change of each IOS index;
R5 (e-i), R20 (e-i), R5-20 (e-i), X5 (e-i), and AX (e-i).
This parameter is calculated as follows; mean value of
expiratory phase minus that of inspiratory phase,
demonstrating the collapse or narrowing of small and
large airways within tidal breathing.6 Recently,
Ohishi et al.38 reported a new approach for assessing
within-breath behavior of oscillatory mechanics for
evaluating the severity of COPD. There were no sig-
nificant differences between group C and T in base-
line patients characteristics, IOS indices and ACTTM
score (Table 2).
All parameters except R20 were significantly im-
proved in group T and no change disclosed in group
C (Fig. 2, Table 3). ACTTM score was significantly im-
proved from 21.94 ± 1.7 to 23.3 ± 1.6 after treatment
with tulobuterol in group T (p < 0.01) (Table 3). In
group T, R5-R20 (e-i) significantly (0.042 kPasL−1 ±
0.03 vs 0.013 kPasL−1 ± 0.03; p < 0.05) improved (Fig.
3), but R5 (e-i), R20 (e-i), X5 (e-i), and AX (e-i) were
not improved (data not shown). Fres was also signifi-
cantly improved in group T and not for group C (Fig.
3).
Next we calculate the change of each parameter
before and 4 weeks after this trial in both group T
and group C. Best correlation showed between the
change in ACTTM score and the change in Fres, sug-
Tanaka H et al.
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Table　3　Effect of 4 week-treatment of transdermal long-acting beta-2 agonist on IOS and ACT score in elderly asthmatic pa-
tients treating with inhaled corticosteroid monotherapy
LABA add-on Group Control Group
p between‡
Baseline 4 weeks P† Baseline 4 weeks P†
R5 0.46 ± 0.14 0.38 ± 0.12 0.0034 0.41 ± 0.18 0.40 ± 0.20 0.5194 0.0191
R20 0.33 ± 0.10 0.31 ± 0.09 0.3957 0.29 ± 0.12 0.30 ± 0.11 0.9377 0.4065
R5-R20 0.13 ± 0.07 0.07 ± 0.05 0.0003 0.11 ± 0.08 0.11 ± 0.10 0.3375 0.0042
R5-R20/R5 27.81 ± 9.03 17.7 ± 9.47 0.0034 26.02 ± 13.34 23.22 ± 9.60 0.3060 0.0267
X5 -0.19 ± 0.09 -0.13 ± 0.06 0.0007 -0.19 ± 0.13 -0.17 ± 0.14 0.0917 0.1489
Fres 19.78 ± 4.27 16.24 ± 5.49 0.0027 20.75 ± 6.77 21.35 ± 5.59 0.4586 0.0007
AX 1.17 ± 0.79 0.63 ± 0.50 <0.0001 1.28 ± 1.11 1.16 ± 1.31 0.1426 0.0201
eR5 0.63 ± 0.50 0.40 ± 0.13 0.0457 0.45 ± 0.20 0.45 ± 0.25 0.4250 0.1824
eR20 0.34 ± 0.11 0.32 ± 0.09 0.3555 0.31 ± 0.12 0.32 ± 0.12 0.9613 0.2875
eR5-R20 0.15 ± 0.09 0.07 ± 0.06 0.0001 0.14 ± 0.11 0.13 ± 0.15 0.2579 0.0291
eX5 -0.19 ± 0.14 -0.12 ± 0.07 0.0005 -0.20 ± 0.16 -0.19 ± 0.21 0.2819 0.0550
eAX 1.36 ± 1.16 0.65 ± 0.64 <0.0001 1.62 ± 1.58 1.51 ± 2.03 0.1928 0.0367
iR5 0.41 ± 0.12 0.36 ± 0.11 0.0161 0.35 ± 0.14 0.34 ± 0.15 0.6799 0.0605
iR20 0.30 ± 0.09 0.29 ± 0.09 0.6277 0.27 ± 0.10 0.26 ± 0.10 0.5520 0.8145
iR5-R20 0.11 ± 0.05 0.06 ± 0.03 0.0005 0.08 ± 0.05 0.08 ± 0.05 0.8149 0.0032
iX5 -0.19 ± 0.07 -0.15 ± 0.06 0.0049 -0.17 ± 0.09 -0.15 ± 0.09 0.0095 0.4359
iAX 1.03 ± 0.57 0.62 ± 0.35 <0.0001 0.92 ± 0.61 0.79 ± 0.59 0.0479 0.0033
ACT 21.94 ± 1.69 23.25 ± 1.61 0.0010 22.47 ± 1.50 22.35 ± 1.66 0.8359 0.0032
†Wilcoxon signed rank test, ‡Wilcoxon rank sum test.
All values presented as mean (SD). Comparison between groups were made with Mann-Whitney U-test. All paired within-subject data 
were evaluated using the Wilcoxon signed rank test, and paired within-group data were assessed by the Wilcoxon rank sum test.
Fig.　3　Therapeutic effects in IOS parameters pre and post 4-week treatment in LABA add on 
group and control group using R5-R20 (e-i): mean value of R5-R20 in expiratory phase minus in 
inspiratory phase and Fres. All paired within-subject data were using the Wilcoxon signed rank 
test. Comparisons between groups were made with the Wilcoxon rank sum test.
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Fig.　4　Relationship between change in asthma symptom score (ACTTM) and change in 
IOS index (Fres) between before and after 4-week treatment in elderly asthmatic patients 
(n = 33), using simple linear regression analysis.
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gesting that change of Fres might reflect asthma
symptoms in elderly asthmatic patients (Fig. 4).
Takeda et al.9 recently described that IOS parameters
correlated better with clinical symptoms and asthma
control than spirometry indices in asthmatic patients.
It was suggested that IOS indices was one of the
good marker to reflect real life asthmatic symptoms
in well-controlled elderly asthma.
Tamura et al. reported that this tulobuterol patch
exerts dose-related add-on effects in patients receiv-
ing ICSs.39 Hozawa et al.7 reported that tulobuterol
patch could be used as a long-term add-on controller
fot asthmatic patients receiving ICS. Hoshino4 de-
scribed that IOS indices of R5-R20, X5, and AX, and
late-phase induced sputum allowed detection of
changes in the small airways that could not be de-
tected by spirometry. Although our study was open
trial, tulobuterol patch might have additional effects
of improving small airways impairment in elderly
asthmatic patients who had treated with ICS alone.
The particles of ICS might insufficiently reach to
complicated destructing and narrowing small airways
by aging, therefore transdermal delivery of LABA
may reach to small airways. IOS may be a useful tool
for detecting subtle airway changes, especially small
airways disease, without any intention.
CONCLUDING REMARKS
This review article mentioned about the usefulness of
IOS, a type of FOT, which is non-invasive and conven-
ient for elderly patients with a low dependency on co-
operation during tidal breathing. National Health In-
surance of Japan covers this examination from April
2012. IOS may have a complemental role to spirome-
try or body plethysmography, However, clinical impli-
cation of each IOS index remains under discussion,
therefore further investigation should be needed in
both basic and clinical area.
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